Madrigal pharmaceuticals exceeds target enrollment in phase 3 maestro nafld-1 trial

Conshohocken, pa., sept. 03, 2020 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl) announced today that it has already exceeded the originally targeted enrollment of 700 patients in its maestro nafld-1 clinical trial of resmetirom in patients with nash and fibrosis that is diagnosed using non-invasive assessments. resmetirom is the first orally administered, small-molecule, liver-directed, truly Β-selective thyroid hormone receptor (thr) agonist currently in phase 3 development for the treatment of nash patients with fibrosis stage 2-3 ( clinicaltrials.gov nct03900429 and clinicaltrials.gov/nct04197479 ).
MDGL Ratings Summary
MDGL Quant Ranking